Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: J Hepatol. 2011 Aug 7;56(1):210–217. doi: 10.1016/j.jhep.2011.07.015

Figure 3. SRC-3 deficiency reduces TCPOBOP-mediated APAP hepatotoxicity.

Figure 3

(A, B) TCPOBOP-pretreated SRC-3−/− mice exhibited dramatically less severe liver injury after APAP (250 mg/kg) administration compared with wild-type mice. Acute liver injury was determined by H&E staining of sections of livers (A) and by measuring ALT levels in serum from both types of mice at 24 h after APAP administration (B) Data are the means + SD of five male mice per group. (C, D) TCPOBOP-pretreated mice deficient in SRC-1−/− (C) or SRC-2−/− mice (D) exhibited severe liver injury similar to wild-type controls after APAP (250 mg/kg) administration. Liver injury was reflected by measurement of ALT levels in serum. Data are the means + SD of four male mice per group. (E) Without TCPOBOP pre-treatment, wild-type and SRC-3−/− mice exhibited similar liver injury after APAP (600 mg/kg) administration. Data are the means + SD of four male mice per group. ** p<0.01.